--- title: "Aberdeen Group plc Raises Stake in Codexis, Inc. $CDXS" type: "News" locale: "en" url: "https://longbridge.com/en/news/281990562.md" description: "Aberdeen Group plc increased its stake in Codexis, Inc. (NASDAQ:CDXS) by 94.7% in Q4, owning 7,966,498 shares valued at approximately $12.99 million. Other institutional investors, including Opaleye Management and Vanguard Group, also raised their holdings. Codexis has a market cap of $179.92 million and reported a quarterly EPS of $0.11, exceeding estimates. Analysts have mixed ratings on the stock, with a consensus rating of \"Hold\" and a target price of $5.00. Codexis specializes in enzyme solutions for various applications." datetime: "2026-04-08T07:06:21.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/281990562.md) - [en](https://longbridge.com/en/news/281990562.md) - [zh-HK](https://longbridge.com/zh-HK/news/281990562.md) --- # Aberdeen Group plc Raises Stake in Codexis, Inc. $CDXS Aberdeen Group plc boosted its position in Codexis, Inc. (NASDAQ:CDXS - Free Report) by 94.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 7,966,498 shares of the biotechnology company's stock after buying an additional 3,874,436 shares during the quarter. Aberdeen Group plc owned approximately 8.82% of Codexis worth $12,985,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Several other hedge funds and other institutional investors have also bought and sold shares of the company. Opaleye Management Inc. boosted its stake in Codexis by 32.6% in the second quarter. Opaleye Management Inc. now owns 12,600,000 shares of the biotechnology company's stock worth $30,744,000 after buying an additional 3,100,000 shares in the last quarter. Vanguard Group Inc. increased its holdings in shares of Codexis by 1.8% in the third quarter. Vanguard Group Inc. now owns 4,669,815 shares of the biotechnology company's stock worth $11,394,000 after buying an additional 80,602 shares during the period. Millennium Management LLC increased its holdings in shares of Codexis by 3,376.5% in the third quarter. Millennium Management LLC now owns 4,067,559 shares of the biotechnology company's stock worth $9,925,000 after buying an additional 3,950,557 shares during the period. Nantahala Capital Management LLC increased its holdings in shares of Codexis by 42.4% in the second quarter. Nantahala Capital Management LLC now owns 4,030,619 shares of the biotechnology company's stock worth $9,835,000 after buying an additional 1,200,000 shares during the period. Finally, Ameriprise Financial Inc. increased its holdings in shares of Codexis by 8.7% in the third quarter. Ameriprise Financial Inc. now owns 2,773,646 shares of the biotechnology company's stock worth $6,768,000 after buying an additional 222,840 shares during the period. Hedge funds and other institutional investors own 78.54% of the company's stock. ## Analyst Upgrades and Downgrades Several research firms have recently commented on CDXS. Stifel Nicolaus set a $5.00 price objective on Codexis in a report on Thursday, March 12th. Weiss Ratings reiterated a "sell (e+)" rating on shares of Codexis in a report on Wednesday, January 21st. Cantor Fitzgerald reiterated an "overweight" rating on shares of Codexis in a report on Thursday, March 12th. Finally, Wall Street Zen upgraded Codexis from a "strong sell" rating to a "hold" rating in a report on Saturday, March 14th. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Hold" and an average target price of $5.00. **Read Our Latest Report on Codexis** ## Codexis Stock Performance Shares of CDXS opened at $1.98 on Wednesday. The company has a debt-to-equity ratio of 0.79, a current ratio of 3.82 and a quick ratio of 3.75. Codexis, Inc. has a one year low of $0.96 and a one year high of $3.87. The company has a 50-day simple moving average of $1.38 and a two-hundred day simple moving average of $1.77. The firm has a market capitalization of $179.92 million, a PE ratio of -3.81 and a beta of 2.08. Codexis (NASDAQ:CDXS - Get Free Report) last issued its quarterly earnings data on Wednesday, March 11th. The biotechnology company reported $0.11 EPS for the quarter, topping the consensus estimate of $0.01 by $0.10. The business had revenue of $38.92 million during the quarter, compared to analyst estimates of $35.83 million. Codexis had a negative net margin of 62.47% and a negative return on equity of 90.51%. On average, analysts anticipate that Codexis, Inc. will post -0.77 EPS for the current fiscal year. ## About Codexis (Free Report) Codexis, Inc, headquartered in Redwood City, California, is a leading protein engineering company focused on the development of innovative enzyme solutions for pharmaceutical, food and beverage, and specialty chemical applications. The company's proprietary directed evolution platform, CodeEvolver®, enables the rapid identification and optimization of enzymes with enhanced activity, selectivity and stability. By leveraging this technology, Codexis provides custom biocatalysts designed to improve manufacturing efficiency and reduce environmental impact. Since its founding in 2002, Codexis has expanded its capabilities from early-stage research to commercial-scale production. ## Further Reading - Five stocks we like better than Codexis **Want to see what other hedge funds are holding CDXS?** Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Codexis, Inc. (NASDAQ:CDXS - Free Report). _This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com._ ## Should You Invest $1,000 in Codexis Right Now? Before you consider Codexis, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Codexis wasn't on the list. While Codexis currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys. View The Five Stocks Here ### Related Stocks - [CDXS.US](https://longbridge.com/en/quote/CDXS.US.md) - [CLDX.US](https://longbridge.com/en/quote/CLDX.US.md) - [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md) - [IBB.US](https://longbridge.com/en/quote/IBB.US.md) - [PBE.US](https://longbridge.com/en/quote/PBE.US.md) - [BIB.US](https://longbridge.com/en/quote/BIB.US.md) - [FBT.US](https://longbridge.com/en/quote/FBT.US.md) - [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md) - [BBH.US](https://longbridge.com/en/quote/BBH.US.md) - [XBI.US](https://longbridge.com/en/quote/XBI.US.md) - [LABU.US](https://longbridge.com/en/quote/LABU.US.md) ## Related News & Research - [Korro Bio To Advance KRRO-111 As Potential Treatment For AATD](https://longbridge.com/en/news/287089978.md) - [BUZZ-Street View: Regeneron's melanoma trial setback raises bigger-picture questions](https://longbridge.com/en/news/286769076.md) - [Roivant posts unexpected Q4 profit due to Moderna lawsuit settlement gain](https://longbridge.com/en/news/287053604.md) - [MiNK Therapeutics' Q1 net loss narrows slightly](https://longbridge.com/en/news/286558132.md) - [Immix Biopharma Announces 95% Complete Response Rate In Interim Update From Relapsed/Refractory AL Amyloidosis Clinical Trial NEXICART-2](https://longbridge.com/en/news/287200923.md)